These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 22137924

  • 21. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 22. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferri C, Foschi V, Galeazzi M, Gerli R, Giardina A, Marchesoni A, Salaffi F, Ziglioli T, Lapadula G, Gruppo Italiano di Studio sulle Early Arthritides (GISEA).
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [Abstract] [Full Text] [Related]

  • 23. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, Walker U.
    Swiss Med Wkly; 2014 Jun; 144():w13950. PubMed ID: 24723273
    [Abstract] [Full Text] [Related]

  • 24. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May 17; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract] [Full Text] [Related]

  • 25. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
    Michaud TL, Rho YH, Shamliyan T, Kuntz KM, Choi HK.
    Am J Med; 2014 Dec 17; 127(12):1208-32. PubMed ID: 24950486
    [Abstract] [Full Text] [Related]

  • 26. Response to: 'Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register)' by Iannone et al.
    Neovius M, Askling J.
    Ann Rheum Dis; 2014 Jun 17; 73(6):e32. PubMed ID: 24638970
    [No Abstract] [Full Text] [Related]

  • 27. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T, Fossati G, Nesbitt A.
    BioDrugs; 2008 Jun 17; 22(5):331-7. PubMed ID: 18778114
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
    Chatzidionysiou K, Askling J, Eriksson J, Kristensen LE, van Vollenhoven R, ARTIS group.
    Ann Rheum Dis; 2015 May 17; 74(5):890-6. PubMed ID: 24431398
    [Abstract] [Full Text] [Related]

  • 29. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN.
    Ophthalmology; 2014 Mar 17; 121(3):785-96.e3. PubMed ID: 24359625
    [Abstract] [Full Text] [Related]

  • 30. Tumor necrosis factor-alpha antagonists: differential clinical effects by different biotechnological molecules.
    Licastro F, Chiappelli M, Ianni M, Porcellini E.
    Int J Immunopathol Pharmacol; 2009 Mar 17; 22(3):567-72. PubMed ID: 19822073
    [Abstract] [Full Text] [Related]

  • 31. [Should we be afraid of the anti-TNFalpha drugs in 2008?].
    Gaudin P.
    Rev Med Interne; 2008 Dec 17; 29(12):971-4. PubMed ID: 18571291
    [No Abstract] [Full Text] [Related]

  • 32. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S, Ferraccioli G, Ferri C, Galeazzi M, Lapadula G, Cerinic MM, Montecucco C, Triolo G, Trotta F, Valentini G.
    Reumatismo; 2009 Dec 17; 61 Suppl 1():1-23. PubMed ID: 19999184
    [Abstract] [Full Text] [Related]

  • 33. [Tumour necrosis factor alpha antagonists in established rheumatoid arthritis: effectiveness comparative study].
    Arenere Mendoza M, Manero Ruiz FJ, Carrera Lasfuentes P, Navarro Aznárez H, Pecondón Español A, Rabanaque Hernández MJ.
    Med Clin (Barc); 2010 May 22; 134(15):665-70. PubMed ID: 20363004
    [Abstract] [Full Text] [Related]

  • 34. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA, Klingman D, Hazard E, Ray S.
    Clin Ther; 2009 Apr 22; 31(4):825-35. PubMed ID: 19446156
    [Abstract] [Full Text] [Related]

  • 35. [Anti-TNF therapy in rheumatoid arthritis].
    Yakeuchi T, Amano K.
    Nihon Rinsho Meneki Gakkai Kaishi; 2004 Feb 22; 27(1):7-15. PubMed ID: 15045810
    [No Abstract] [Full Text] [Related]

  • 36. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    Semin Arthritis Rheum; 2014 Feb 22; 43(4):447-57. PubMed ID: 24012040
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J, Sieper J, Weiß A, Zink A, Listing J.
    Ann Rheum Dis; 2015 Jun 22; 74(6):1241-8. PubMed ID: 24718959
    [Abstract] [Full Text] [Related]

  • 38. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM, Shalaby MA, Al-Homaid S, Mahfouz AM, Shams OA, Fathy A.
    Int J Rheum Dis; 2012 Jun 22; 15(3):330-5. PubMed ID: 22709496
    [Abstract] [Full Text] [Related]

  • 39. High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis.
    Daïen CI, Gailhac S, Audo R, Mura T, Hahne M, Combe B, Morel J.
    Rheumatology (Oxford); 2015 Apr 22; 54(4):601-8. PubMed ID: 25231180
    [Abstract] [Full Text] [Related]

  • 40. The yin and yang of tumor necrosis factor inhibitors.
    Calabrese L.
    Cleve Clin J Med; 2006 Mar 22; 73(3):251-6. PubMed ID: 16548447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.